A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Enrolling participants
Planned enrollment: 110 participants
Study ages: 2 Years to 17 Years
Recruiting sites listed in: Belgium, Bulgaria, Canada, China, France and 15 more countries/territories (see details)
No results-posting date in this record
Read trial record and resultsChecked Nov 16, 2026